ClinicalTrials.gg
Not yet recruitingNCT07850375HSCT-NUTUpdated Sep 30, 2026

Nutritional Intervention for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

An interventional study of Enteral Nutritional Suspension (TP-MCT) and Routine nutritional guidance in Hematopoietic Stem Cell Transplantation (HSCT) and Malnutrition (Calorie), sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Supportive care

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Malnutrition with a site in China — 20 open to participants now, 21 under way, 1 of them phase 3. Malnutrition · China.

Planned enrollment
15th of 32
160 · median 120
Started
2026
with 3 others
No phase
19 of 59
8 open now
Primary completion
2027-10
later than 13 of 20 live
Registered
59th of 59
by date

Among the 59 studies in Malnutrition with a site in China, this one is the 15th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2026, is one of 19 with no phase, reaches primary completion later than 13 of the 20 other live ones, and was the 59th registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

20 of the 59 studies in Malnutrition with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Malnutrition with a site in China, or all of them as a file.
02

Study summary

This is a multi-center observational study. The study aims to explore the effect of enteral nutritional support on nutritional status and clinical outcomes in patients after hematopoietic stem cell transplantation. Eligible participants will receive routine clinical care combined with nutritional intervention at each participating site. We will collect clinical and laboratory indicators to evaluate changes in nutrition-related indexes. No extra invasive procedures will be performed for research purposes.

Read the detailed description

This is a multi-center, open-label, parallel-group randomized controlled study to investigate the effects of peri-transplant oral nutritional supplement (ONS) intervention on clinical disease outcomes among adult patients undergoing myeloablative allogeneic hematopoietic stem-cell transplantation (allo-HSCT).

Malnutrition occurs frequently in allo-HSCT recipients and is associated with higher risks of graft-versus-host disease (GVHD), transplant-related mortality, infection, and poor survival. Malnutrition, intestinal barrier injury and gut microbiota dysbiosis form a vicious cycle that worsens post-transplant complications. In addition, sleep disturbance and obstructive sleep apnea (OSA) are highly prevalent during transplantation and may mediate the relationship between nutritional status and transplant prognosis, which has rarely been objectively evaluated in existing nutrition-related transplant studies. Non-contact millimeter-wave radar-based sleep-breathing monitoring will be applied in this trial to objectively capture sleep-respiratory parameters without wearable devices.

A total of 160 eligible participants will be enrolled in this three-center multicenter study across three Chinese clinical sites (100 participants at the lead center, 30 participants at each of the two collaborative sites), and randomized at a 1:1 ratio within each center into either the intervention group or the control group (80 participants per arm). Randomization will be performed independently within each participating center. All participants will receive routine dietary and physical-activity guidance according to study manuals.

Participants assigned to the intervention group will receive daily 500 mL Kangquan-Gan enteral nutrition suspension (1 kcal/mL, polymeric whole-protein formula, 500 kcal per bottle, oral nutritional supplement). The initial administration starts at 20-50 mL with 2-3 h during the study observation; if gastrointestinal tolerance is acceptable, the dose will be gradually titrated up to the target 500 mL per day in divided doses (50-100 mL, 4-6 times daily). If gastrointestinal adverse reactions occur, ONS will be paused for 1-3 days and re-challenged. Persistent intolerance will lead to study withdrawal. Remaining energy requirements will be covered by regular oral diet. Parenteral nutrition (PN) will be supplemented when total energy intake continuously falls below 60 % of target energy for 3-5 consecutive days.

Participants in the control group will receive standard nutritional support with identical dietary guidance, without study-provided ONS. Daily dietary intake will be recorded. Parenteral nutrition will be used to compensate energy shortfalls to meet individual energy and protein targets. To reduce performance bias caused by heightened awareness of nutritional intake among control participants, participants from two study arms will be housed on separate wards whenever feasible.

Target energy is calculated as the sum of ONS, parenteral nutrition and ordinary dietary intake. Nutritional support teams (physicians, nurses, dietitians, pharmacists) will monitor daily energy intake and adjust nutritional strategies dynamically according to subject tolerance and clinical conditions. During the intervention period, participants are required to avoid other enteral nutritional products, probiotics and prebiotics that may interfere with study outcomes. Unintended consumption will be documented in case report forms.

Study assessments, physical measurements and biological sample collection will be performed at seven scheduled time-points: baseline (approximately 7 days before conditioning initiation), day 1 of conditioning, stem-cell infusion day, neutrophil engraftment (day +14 post-infusion), post-transplant day 30, day 60 and day 90. Collected biospecimens include stool samples (40 g of the first voided stool of the day at each time-point) for gut microbiota analysis. Fresh stool specimens will be transported to the key laboratory within 2 hours under 4 °C cold-chain conditions, processed and stored long-term at -80 °C for laboratory analyses. Evaluations cover anthropometrics, body-composition analysis, handgrip strength, nutritional assessment (NRS-2002, PG-SGA), laboratory biochemistry, hematology, inflammatory cytokines, immune-cell subsets, bone-marrow examinations, non-contact sleep-apnea monitoring, EORTC-QLQ-C30 quality-of-life questionnaire, 24-hour dietary recall and gastrointestinal symptom rating scale (GSRS).

Primary outcome measures include overall survival, transplant-related mortality, and cumulative incidence of acute graft-versus-host disease (aGVHD). Secondary outcomes cover incidence of conditioning-related toxicity, adverse-event rates, changes in BMI Z-score, body-fat percentage, skeletal-muscle mass, handgrip strength, and incidence of obstructive sleep apnea. Exploratory endpoints contain neutrophil and platelet engraftment time, albumin transfusion volume, antimicrobial-agent consumption, length of hospital stay and total hospitalization costs. Safety outcomes focus on the incidence of acute pancreatitis, hypersensitivity, grade-4 oral mucositis, refractory vomiting, and moderate-to-severe diarrhea; secondary safety variables include general adverse-event rates and abnormalities of liver- and renal-function laboratory parameters. Adverse events will be graded using CTCAE Version 5.0.

After completion of the 90-day intensive observation phase, all participants will undergo long-term follow-up via outpatient visits, telephone and WeChat contact up to 3 years post-transplant at scheduled time-points (6-month, 9-month, 1-year, 1.5-year, 2-year, 2.5-year, 3-year).

Primary analysis will be performed on the Full-Analysis Set (FAS); safety analysis will be based on the Safety-Set (SS); Per-Protocol-Set (PPS) will be used for sensitivity analysis. Statistical analyses will be performed using SAS 9.4. Cox proportional-hazards regression, logistic regression, repeated-measures analysis of variance, chi-square test, Fisher's exact test, t-test and Wilcoxon rank-sum test will be applied as appropriate. All statistical tests will be two-sided with α = 0.05.

Written informed consent must be obtained before any study-specific procedures. This trial complies with the Declaration of Helsinki. The study protocol, informed-consent documents and amendments are reviewed and approved by the institutional review board of the lead study site as well as ethics committees of each participating center.

03

Conditions studied

  • Hematopoietic Stem Cell Transplantation (HSCT)
  • Malnutrition (Calorie)

Keywords

  • llogeneic hematopoietic stem cell transplantation
  • Oral nutritional supplement
  • Enteral nutrition
  • Malnutrition
  • Graft-versus-host disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with primary hematological diseases of acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome who have an indication for hematopoietic stem cell transplantation (Allo-HSCT) and are scheduled to undergo myeloablative conditioning;
  2. Expected survival ≥ 3 months;
  3. Age between 18 and 65 years (inclusive), with no restrictions on sex or race;
  4. performance status ≤ 2;
  5. NRS2002 score ≥ 3;
  6. The patient, or his/her authorized legal representative, agrees to participate in the clinical trial and signs the form.

Exclusion criteria

Exclusion Criteria:

  1. acute myeloid leukemia;
  2. Acute myeloid leukemia, myelodysplastic syndrome and acute lymphoblastic leukemia with positive MRD prior to transplantation;
  3. Patients with concomitant other malignant tumors requiring treatment;
  4. Presence of active infections, such as , , tuberculosis, etc.;
  5. Patients with positive serology;
  6. Patients with impairment of one or more major organs including heart, lung, liver and kidney, severe abnormal glucose metabolism, or those assessed by the investigator as unable to tolerate treatment;
  7. Patients with clinical symptoms of cerebral dysfunction, severe psychiatric disorders, or other conditions rendering them unable to understand or comply with treatment and monitoring requirements;
  8. Regular use of enteral nutrition preparations within 1 month prior to study entry;
  9. Suspected allergy to the product or any of its ; Patients deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    ONS Nutritional Intervention Group

    Participants receive 500 mL Kangquangan enteral nutrition suspension (whole-protein formula, 1 kcal/mL, Nutricia Pharmaceutical (Wuxi) Co., Ltd.) daily, combined with routine dietary guidance. Additional parenteral nutrition will be supplemented if daily energy intake continuously fails to reach 60% of target energy for 3-5 consecutive days. Dose titration: initial 20-50 mL, gradually escalated to target dose according to gastrointestinal tolerance.

    Dietary Supplement: Enteral Nutritional Suspension (TP-MCT) · Behavioral: Routine nutritional guidance · Other: Biospecimen-Stool Sample Collection · Other: Non-contact Millimeter-Wave Radar Sleep-Breathing Monitoring

  • Active comparator
    Routine Nutritional Support Group

    Participants receive routine dietary guidance without oral nutritional supplement. Parenteral nutrition will be supplemented to meet target energy requirements when oral intake is insufficient.

    Behavioral: Routine nutritional guidance · Other: Biospecimen-Stool Sample Collection · Other: Non-contact Millimeter-Wave Radar Sleep-Breathing Monitoring

Interventions

  • Dietary supplementEnteral Nutritional Suspension (TP-MCT)

    500 mL per day of enteral nutritional suspension (TP-MCT), whole-protein formula, 1 kcal/mL, administered orally in addition to routine dietary guidance. Dose titrated from 20-50 mL initial volume to target dose according to gastrointestinal tolerance. Provided by Nutricia Pharmaceutical (Wuxi) Co., Ltd.

  • BehavioralRoutine nutritional guidance

    Standard clinical dietary guidance without oral nutritional supplement. Parenteral nutrition will be supplemented to meet target energy requirements when oral intake is insufficient.

  • OtherBiospecimen-Stool Sample Collection

    Collection of 40 g first-voided fresh stool samples at seven predefined study time-points for gut microbiota analysis. Specimens are transported under 4 °C cold-chain conditions and stored long-term at -80 °C for laboratory testing.

  • OtherNon-contact Millimeter-Wave Radar Sleep-Breathing Monitoring

    24-hour non-contact sleep-breathing monitoring is performed via millimeter-wave radar device on the day of conditioning initiation and on the day of stem-cell infusion. No wearable sensors are required for participants to collect sleep-respiratory parameters.

06

What researchers measure

Primary outcomes

  1. Incidence of Acute Graft-versus-Host Disease (aGVHD)

    Cumulative incidence of acute graft-versus-host disease (skin, gastrointestinal tract, liver) assessed by modified Glucksberg / MAGIC grading criteria.

    Time frame: Within 100 days after transplantation

  2. 3-year Overall Survival Rate

    Overall survival rate, defined as the proportion of participants alive at 3-year follow-up after allogeneic hematopoietic stem-cell transplantation; death from any cause is treated as event.

    Time frame: 3 years after allogeneic hematopoietic stem-cell transplantation

  3. 3-year Transplant-Related Mortality

    Cumulative incidence of transplant-related mortality within 3 years after hematopoietic stem cell transplantation.

    Time frame: From Day 0 after hematopoietic stem cell transplantation until the date of transplant-related death, assessed up to 3 years

Secondary outcomes

  1. Incidence of conditioning-related toxicity

    Toxicity graded by NCI-CTCAE 5.0, count cases of grade ≥2 toxicity

    Time frame: From initiation of conditioning to 30 days post-infusion

  2. Incidence of obstructive sleep apnea(OSA)

    Obstructive sleep apnea was detected by non-contact sleep-breath monitoring using millimeter-wave radar.

    Time frame: Day of conditioning, Day 0 (stem-cell infusion day) after hematopoietic stem cell transplantation

  3. Body weight

    Body weight is measured in participants.

    Time frame: Baseline (7 days before conditioning), Conditioning Day, Day 0, Day 14, Day 30, Day 60, Day 90 after hematopoietic stem cell transplantation

  4. Handgrip strength

    Hand dynamometer; dominant hand measured 3 times for average value

    Time frame: Baseline (7 days before conditioning), Day of conditioning, Day 0, Day 14, Day 30, Day 60, Day 90 after hematopoietic stem cell transplantation

  5. Incidence of adverse events

    Incidence of adverse events occurring in participants from the date of signed informed consent throughout oral nutritional supplement intervention period, graded according to CTCAE Version 5.0.

    Time frame: From the date of signed informed consent up to Day 90 after hematopoietic stem cell transplantation

  6. Patient-Generated Subjective Global Assessment (PG-SGA) score

    Complete Patient-Generated Subjective Global Assessment (PG-SGA) questionnaire and calculate total score. The PG-SGA total score ranges from 0 to 35; higher scores indicate greater severity of malnutrition.

    Time frame: Baseline (7 days before conditioning), Day of conditioning, Day 0, Day 14, Day 30, Day 60, Day 90 after hematopoietic stem cell transplantation

  7. Phase angle

    Phase angle is measured by bioelectrical impedance analysis (BIA) in participants.

    Time frame: Baseline (7 days before conditioning), Day of conditioning, Day 0, Day 14, Day 30, Day 60, Day 90 after hematopoietic stem cell transplantation

Other outcomes

  1. Time to neutrophil engraftment

    Days from stem-cell infusion to sustained absolute neutrophil count ≥0.5×10\^9/L for 3 consecutive days.

    Time frame: Up to day +28 after transplantation

  2. Time to platelet engraftment

    Days from stem-cell infusion to sustained platelet count ≥20×10\^9/L without platelet transfusion support for 7 consecutive days.

    Time frame: Up to day +28 after transplantation

  3. Hospital length of stay

    Total days of inpatient hospitalization during transplant treatment for participants.

    Time frame: From admission for transplantation to hospital discharge, assessed up to 1 year after hematopoietic stem cell transplantation

  4. Medical resource consumption

    Consumption of albumin preparations, antimicrobial agents and total hospitalization-related costs.

    Time frame: Up to day +90 after transplantation

  5. Abnormalities in key laboratory parameters

    Abnormal changes of ALT, total bilirubin and serum creatinine.

    Time frame: Baseline up to day +90 after transplantation

  6. Incidence of nutrition-related severe adverse events

    Incidence of pancreatitis, hypersensitivity, grade 4 oral mucositis, refractory vomiting, moderate-to-severe diarrhea.

    Time frame: From study enrollment to day +90 after transplantation

  7. Anthropometric circumferences

    Waist circumference, hip circumference, upper arm circumference and calf circumference are measured in participants.

    Time frame: Baseline (7 days before conditioning), Conditioning Day, Day 0, Day 14, Day 30, Day 60, Day 90 after hematopoietic stem cell transplantation

  8. Body composition mass parameters assessed by bioelectrical impedance analysis (BIA)

    Lean body mass, fat mass, total body water, skeletal muscle mass and bone mineral content are measured by bioelectrical impedance analysis (BIA) in participants.

    Time frame: Baseline (7 days before conditioning), Conditioning Day, Day 0, Day 14, Day 30, Day 60, Day 90 after hematopoietic stem cell transplantation.

  9. Body composition percentage parameters assessed by bioelectrical impedance analysis (BIA)

    Body fat percentage, skeletal muscle percentage and total body water percentage are measured by bioelectrical impedance analysis (BIA) in participants.

    Time frame: Baseline (7 days before conditioning), Conditioning Day, Day 0, Day 14, Day 30, Day 60, Day 90 after hematopoietic stem cell transplantation.

  10. Serious adverse event incidence

    Incidence of serious adverse events occurring in participants, defined according to ICH-GCP criteria.

    Time frame: From the date of signed informed consent, assessed up to 3 years after hematopoietic stem cell transplantation

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared with other external researchers. Analyzed aggregate study results may be published in peer-reviewed journals.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 393 non-industry interventional studies with no phase under Malnutrition, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 419 studies reached it within 22 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 30, 2026
StartEst.
Oct 12, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Oct 30, 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850375
Collaborators
Nutricia Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 12, 2026 (estimated)
Primary completion
Oct 30, 2027 (estimated)
Completion
Oct 30, 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

Jingqin Sun, M.Med
Contact
sunjingqin@ihcams.ac.cn
+86-22-23608209
Jingqin Sun, M.Med
principal investigator · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion